Effect of metformin on serum visfatin levels in patients with polycystic ovary syndrome

Fertility and Sterility

Volumn 93, Issue 3, 2010, Pages 880-884

  Ozkaya, Mesut ^a   Cakal, Erman ^b   Ustun, Yusuf ^c   Engin Ustun, Yaprak ^c  

^a KAHRAMANMARAS SUTCU IMAM UNIVERSITY   (Turkey)

^b Yuksek Ihtisas Heart Education and Research Hospital   (Turkey)

^c INONU UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PRASTERONE SULFATE; THYROXINE; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME BLOOD LEVEL; FEMALE; FREE THYROXINE INDEX; HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

ADULT; BLOOD GLUCOSE; BODY MASS INDEX; CROSS-SECTIONAL STUDIES; CYTOKINES; DIABETES MELLITUS, TYPE 2; FEMALE; HOMEOSTASIS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LIPIDS; METFORMIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; POLYCYSTIC OVARY SYNDROME; RISK FACTORS; SENSITIVITY AND SPECIFICITY; WAIST CIRCUMFERENCE; YOUNG ADULT;

EID: 75749115194     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2008.10.058     Document Type: Article

References (22)

1. Azziz R., Woods K.S., Reyna R., Key T.J., Knochenhauer E.S., and Yildiz B.O. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 89 (2004) 2745-2749
2. Ustun-Engin Y., Ustun Y., Meydanli{dotless} M.M., Kafkasli{dotless} A., and Yetkin G. Are polycystic ovaries associated with cardiovascular disease risk as polycystic ovary syndrome?. Gynecol Endocrinol 22 (2006) 324-328
3. Fukuhara A., Matsuda M., Nishizawa M., Segawa K., Tanaka M., Kishimoto K., et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307 (2005) 426-430
4. Berndt J., Kloting N., Kralisch S., Kovacs P., Fasshauer M., Schon M.R., et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 54 (2005) 2911-2916
5. Chen M.P., Chung F.M., Chang D.M., Tsai J.C.R., Huang H.-F., Shin S.J., et al. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 91 (2006) 295-299
6. Tan B.K., Chen J., Digby J.E., Keay S.D., Kennedy C.R., and Randeva H.S. Increased visfatin messenger ribonucleic acid and protein levels in adipose tissue and adipocytes in women with polycystic ovary syndrome: parallel increase in plasma visfatin. J Clin Endocrinol Metab 91 (2006) 5022-5028
7. Chan T.F., Chen Y.L., Chen H.H., Lee C.H., Jong S.B., and Tsai E.M. Increased plasma visfatin concentrations in women with polycystic ovary syndrome. Fertil Steril 88 (2007) 401-405
8. Kowalska I., Straczkowsi M., Nikolajuk A., Adamska A., Karczewska-Kupczewska M., Otziomek E., et al. Serum visfatin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome. Hum Reprod 22 (2007) 1824-1829
9. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 81 (2004) 19-25
10. Hatch R., Rosenfield R.L., Moon H.K., and Tredway D. Hirsutism: implications, etiology and management. Am J Obstet Gynecol 140 (1981) 815-830
11. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., and Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
12. Arner P. Insulin resistance in type 2 diabetes-role of adipokines. Curr Mol Med 5 (2005) 333-339
13. Sozen I., and Arici A. Hyperinsulinism and its interaction with hyperandrogenism in polycystic ovary syndrome. Obstet Gynecol Survey 55 (2000) 321-328
14. Krzyzanowska K., Krugluger W., Mittermayer F., Rahman R., Haider D., Shnawa N., et al. Increased visfatin concentrations in women with gestational diabetes mellitus. Clin Sci 110 (2006) 605-609
15. Lewandowski K.C., Stojanovic N., Press M., Tuck S.M., Szosland K., Bienkiewicz M., et al. Elevated serum levels of visfatin in gestational diabetes: a comparative study across various degrees of glucose tolerance. Diabetologia 50 (2007) 1033-1037
16. Haider D.G., Schaller G., Kapiotis S., Maier C., Luger A., and Wolzt M. The release of the adipocytokine visfatin is regulated by glucose and insulin. Diabetologia 46 (2006) 1909-1914
17. Hsieh C.H., He C.T., Lee C.H., Wu L.Y., and Hung Y.J. Both slow-release and regular-form metformin improve glycemic control without altering plasma visfatin level in patients with type 2 diabetes mellitus. Metabolism 56 (2007) 1087-1092
18. Takebayashi K., Suetsugu M., Wakabayashi S., Aso Y., and Inukai T. Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus. Metabolism 56 (2007) 451-458
19. Kolodziejczyk B., Duleba A.J., Spaczynski R.Z., and Pawelczyk L. Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome. Fertil Steril 73 (2000) 1149-1154
20. Diamanti-Kandarakis E. Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. Eur J Endocrinol 138 (1998) 269-274
21. Nawrocka J., and Starczewski A. Effects of metformin treatment in women with polycystic ovary syndrome depends on insulin resistance. Gynecol Endocrinol 23 (2007) 231-237
22. Lord J.M., Flight I.H., and Norman R.J. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. Br Med J 327 (2003) 951-957